Biosimilar

Adalimumab biosimilar BI 695501 demonstrated similar safety and efficacy compared with adalimumab reference product among patients with Crohn’s disease, according to research published in the Lancet Gastroenterology and Hepatology.

The American Academy of Ophthalmology has asked CMS and HHS to prohibit Medicare Advantage and exchange plans from suggesting biosimilar alternatives to Avastin, according to a press release.

The FDA approved the first interchangeable biosimilar insulin product to improve glycemic control for children and adults with diabetes, part of an effort to provide cost-effective options, according to an agency press release.

Patients with inflammatory bowel disease who switched from one infliximab biosimilar to another had no significant change in disease activity, according to research published in Alimentary Pharmacology and Therapeutics.

On May 11, Icelandic-based drug developer Alvotech filed a lawsuit against AbbVie seeking to undo what it alleges is a “minefield” of “invalid” patents surrounding what is arguably the pharma giant’s most prized possession: Humira.

During a recent event hosted by the Rheumatology Research Foundation, Jeffrey R. Curtis, MD, MS, MPH, said that COVID-19 vaccine boosters could potentially become common among immunocompromised patients.

The U.S. Supreme Court has denied a petition from Novartis’ Sandoz to review an earlier U.S. appeals court ruling in favor of Amgen’s etanercept against etanercept-szzs, effectively blocking the biosimilar from entering the U.S. market.

Patients with hidradenitis suppurativa who were treated with the biosimilar infliximab-abda experienced similar improvement in their condition as those who received infliximab, according to a study.

The intravenous and subcutaneous formulations of Remsima had comparable efficacy, safety and immunogenicity profiles in patients with inflammatory bowel disease, according to study results.

The adalimumab biosimilar CT-P17 demonstrates equivalent efficacy, and comparable safety and immunogenicity, to its reference product in patients with rheumatoid arthritis, according to data published in Arthritis Research & Therapy.